title: US Food and Drug Administration Approval of Flibanserin: Even the Score Does Not Add Up.
authors.affiliation: Center for Medicine and the Media, Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, New Hampshire2Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
authors.forename: Steven
authors.initials: S
authors.lastname: Woloshin
authors.affiliation: Center for Medicine and the Media, Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, New Hampshire2Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Schwartz
mesh_terms: D001562:Benzimidazoles / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D017277:Drug Approval; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D017060:Patient Satisfaction; D020018:Sexual Dysfunctions, Psychological / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D001562:Benzimidazoles; C098107:flibanserin